Send us Feedback

Cel-Sci (CVM)
Analysis
SUMMARY
BULLS
BEARS
Data
DATA CENTRAL
STOCK CHART
Financials
SEC FILINGS
BALANCE
INCOME
CASH FLOW
QUOTE AND NEWS
Biotech Stock Mailbag: ASCO, Sarepta, Cel-Sci and Hate Mail!
TheStreet.com  Apr 26  Comment 
BOSTON (TheStreet) -- I'm trying to incorporate more actual tweets in the Biotech Stock Mailbag. @adamfeuerstein Adam, ASCO review in the works? Especially heads up for abstracts of note which are soon.— Greg Tucker (@GregTucker21) April...
UPDATE: CEL-SCI Announces NIAID Collaborators Have Submitted Bird Flu Study for Publication to Scientific Journal
Benzinga  Apr 8  Comment 
CEL-SCI Corporation (NYSE: CVM) today announced that its collaborators at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, USA, have submitted for publication to a...
CEL-SCI Corp. (CVM) Narrows Q1 Loss to 1c/Share
StreetInsider.com  Feb 8  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/CEL-SCI+Corp.+%28CVM%29+Narrows+Q1+Loss+to+1cShare/8075243.html for the full story.
Cel-Sci (CVM) Files $50M Mixed Shelf
StreetInsider.com  Jan 22  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Equity+Offerings/Cel-Sci+%28CVM%29+Files+%2450M+Mixed+Shelf/8021850.html for the full story.
CEL-SCI Corporation (CVM) to Sell 35M Common at 30c/Share
StreetInsider.com  Dec 4  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Equity+Offerings/CEL-SCI+Corporation+%28CVM%29+to+Sell+35M+Common+at+30cShare/7921277.html for the full story.
CEL-SCI Corporation to Raise $10.5M in Registered Direct Offering
Benzinga  Dec 4  Comment 
CEL-SCI Corporation (NYSE: CVM), a late-stage oncology company, has entered into a definitive agreement to sell 35 million shares of its common stock at a price per share of $0.30 in a registered direct offering to institutional investors,...
CEL-SCI Says Interim Review of Ongoing Phase 3 Trial Showed No safety Concerns
Benzinga  Oct 22  Comment 
CEL-SCI Corporation (NYSE MKT: CVM) announced today that an interim review of the safety data from its open label, randomized, controlled, pivotal Phase III study of Multikine (Leukocyte Interleukin, Injection) investigational immunotherapy by an...
CEL-SCI (CVM) Reports Multikine Phase III Raised No Safety Concerns for IDMC
StreetInsider.com  Oct 22  Comment 
CEL-SCI Corp. (CVM) Files $50M Mixed Shelf
StreetInsider.com  Sep 25  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Equity+Offerings/CEL-SCI+Corp.+%28CVM%29+Files+%2450M+Mixed+Shelf/7750567.html for the full story.
CEL-SCI Corp. (CVM) Reports Q2 Earnings of $0.00
StreetInsider.com  Aug 9  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/CEL-SCI+Corp.+%28CVM%29+Reports+Q2+Earnings+of+%240.00/7648593.html for the full story.
CVM Solutions Launches Diversity Spend Analytics
Marketwire  Jun 26  Comment 
CHICAGO, IL -- (Marketwire) -- 06/26/12 -- CVM Solutions, a premier provider of supplier management solutions, today launched CVM Diversity Spend Analytics, adding the most comprehensive analytics tool available in the market to its suite of leading




more ▼WIKI ANALYSIS
 

CEL-SCI is dedicated to research and development directed at improving the treatment of cancer and other diseases by utilizing the immune system, the body's natural defense system.

CEL-SCI's lead investigational therapy, Multikine® (Leukocyte Interleukin, Injection), is an immunotherapeutic agent being developed as a potential first-line treatment for advanced primary head and neck cancer. Data from Phase I and Phase II clinical trials suggest that Multikine simulates the activities of a healthy person's immune system, enabling it to use the body's own anti-tumor immune response. Multikine (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in the remainder of this page as Multikine*.


References

Retrieved from "http://www.wikinvest.com/stock/Cel-Sci_(CVM)"
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki